A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases
Status: Recruiting
Location: See all (18) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Capable of giving signed informed consent.
• Adequate physiological function and reserve at screening.
• Able to comply with recommended medication washout period.
• Participants who are suitable for the study as determined by medical evaluation and at the discretion of the investigator.
• Willingness to remain on/start appropriate, highly effective methods of birth control or other acceptable criteria.
Locations
United States
Arizona
Research Site
NOT_YET_RECRUITING
Tucson
California
Research Site
NOT_YET_RECRUITING
Stanford
Illinois
Research Site
NOT_YET_RECRUITING
Chicago
Michigan
Research Site
NOT_YET_RECRUITING
Ann Arbor
Missouri
Research Site
NOT_YET_RECRUITING
St Louis
North Carolina
Research Site
NOT_YET_RECRUITING
Chapel Hill
New York
Research Site
RECRUITING
New York
Washington
Research Site
NOT_YET_RECRUITING
Seattle
Other Locations
Australia
Research Site
RECRUITING
Darlinghurst
Research Site
NOT_YET_RECRUITING
Waratah
Germany
Research Site
NOT_YET_RECRUITING
Hamburg
Research Site
NOT_YET_RECRUITING
Mainz Am Rhein
Research Site
NOT_YET_RECRUITING
Würzburg
Spain
Research Site
NOT_YET_RECRUITING
Barcelona
Research Site
NOT_YET_RECRUITING
Madrid
Research Site
NOT_YET_RECRUITING
Madrid
United Kingdom
Research Site
NOT_YET_RECRUITING
Edinburgh
Research Site
NOT_YET_RECRUITING
London
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2026-01-09
Estimated Completion Date: 2028-02-22
Participants
Target number of participants: 27
Treatments
Experimental: AZD0120 Regimen 1
Participants will receive an infusion of AZD0120 Regimen 1.
Experimental: AZD0120 Regimen 2
Participants will receive an infusion of AZD0120 Regimen 2.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca